β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
CONTEXT: beta-Blocker therapy remains substantially underused in cardiac patients despite its proven mortality benefits. Reluctance to prescribe these agents may derive from concerns about their association with symptoms of depression, fatigue, and sexual dysfunction. OBJECTIVE: To determine the association of beta-blockers with depressive symptoms, fatigue, and sexual dysfunction by performing a quantitative review of randomized trials that tested beta-blockers in myocardial infarction, heart failure, and hypertension. DATA SOURCES: Randomized trials of beta-blockers used in the treatment of myocardial infarction, heart failure, or hypertension were identified by searching the MEDLINE database for English-language articles (1966-2001). In addition, we searched the reference lists of previously published trials and reviews of beta-blockers for additional studies. STUDY SELECTION: Criteria for inclusion of trials in the review were: random allocation of study treatments, placebo control, noncrossover design, enrollment of at least 100 patients, and a minimum of 6 months of follow-up. The initial search produced 475 articles, 42 of which met these criteria. Fifteen of these trials reported on depressive symptoms, fatigue, or sexual dysfunction and were selected for inclusion. DATA EXTRACTION: For each trial, 1 author abstracted the frequency of adverse events in the beta-blocker and placebo groups and the numbers of patients randomized to the treatment groups. Two other authors verified the counts of events, and all authors adjudicated any discrepancies. Two different types of information on adverse events were abstracted: patient-reported symptoms and withdrawal of therapy due to a specified symptom. We categorized the tested beta-blockers by generation (early vs late) and lipid solubility (high vs low to moderate). DATA SYNTHESIS: The 15 trials involved more than 35,000 subjects. beta-Blocker therapy was not associated with a significant absolute annual increase in risk of reported depressive symptoms (6 per 1000 patients; 95% confidence interval [CI], -7 to 19). beta-Blockers were associated with a small significant annual increase in risk of reported fatigue (18 per 1000 patients; 95% CI, 5-30), equivalent to 1 additional report of fatigue for every 57 patients treated per year with beta-blockers. beta-Blockers were also associated with a small, significant annual increase in risk of reported sexual dysfunction (5 per 1000 patients; 95% CI, 2-8), equivalent to one additional report for every 199 patients treated per year. None of the risks of adverse effects differed significantly by degree of beta-blocker lipid solubility. The risk associated with reported fatigue was significantly higher for early-generation than for late-generation beta-blockers (P =.04). CONCLUSION: The conventional wisdom that beta-blocker therapy is associated with substantial risks of depressive symptoms, fatigue, and sexual dysfunction is not supported by data from clinical trials. There is no significant increased risk of depressive symptoms and only small increased risks of fatigue and sexual dysfunction. The risks of these adverse effects should be put in the context of the documented benefits of these medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Heart Disease: A Textbook of Cardiovascular Medicine.
(1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-3-415_3 · Cited by 4,109
The Handbook of Research Synthesis.
Howel, D., Cooper, H., & Hedges, L. V. (1995) · Biometrics · doi:10.2307/2533295 · Cited by 3,642
Arky, R. A. (1994) · Cited by 2,632
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
beta Blockade after myocardial infarction: systematic review and meta regression analysis
Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J. (1999) · BMJ · doi:10.1136/bmj.318.7200.1730 · Cited by 1,509
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Medical Research Council trial of treatment of hypertension in older adults: principal results.
Peart, S., Brennan, P. J., Broughton, P., Dollery, C. T., Hudson, M. F., Lever, A. F., Meade, T. W., Rose, G., & Pocock, S. (1992) · Cited by 1,360
β-Adrenergic Receptor Blockade in Chronic Heart Failure
Bristow, M. R. (2000) · Circulation · doi:10.1161/01.cir.101.5.558 · Cited by 1,028
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Authors/Task Force Members (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,336
Riegel, B., Moser, D. K., Anker, S. D., Appel, L. J., Dunbar, S. B., Grady, K. L., Gurvitz, M. Z., Havranek, E. P., Lee, C. S., Lindenfeld, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192628 · Cited by 961
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Fatigue in long‐term breast carcinoma survivors: A longitudinal investigation
Bower, J. E., Ganz, P. A., Desmond, K. A., Bernaards, C., Rowland, J. H., Meyerowitz, B. E., & Belin, T. R. (2006) · Cancer · doi:10.1002/cncr.21671 · Cited by 694
Tardif, J.-C., Ford, I., Tendera, M., Bourassa, M. G., & Fox, K. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi586 · Cited by 582
Brain mechanisms of insomnia: new perspectives on causes and consequences
Van Someren, E. J. W. (2021) · Physiological Reviews · doi:10.1152/physrev.00046.2019 · Cited by 543
The influence of age, gender, and race on the prevalence of depression in heart failure patients
Gottlieb, S. S., Khatta, M., Friedmann, E., Einbinder, L., Katzen, S., Baker, B., Marshall, J., Minshall, S., Robinson, S., Fisher, M. L., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.064 · Cited by 467
Guidelines for the Pharmacologic Treatment of Neurobehavioral Sequelae of Traumatic Brain Injury
Warden, D. L., Gordon, B., McAllister, T. W., Silver, J. M., Barth, J. T., Bruns, J., Drake, A., Gentry, T., Jagoda, A., Katz, D. I., et al. (2006) · Journal of Neurotrauma · doi:10.1089/neu.2006.23.1468 · Cited by 438
Montorsi, P., Ravagnani, P. M., Galli, S., Rotatori, F., Veglia, F., Briganti, A., Salonia, A., Deho, F., Rigatti, P., Montorsi, F., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl142 · Cited by 420
van Esser, J. W. J., van der Holt, B., Meijer, E., Niesters, H. G. M., Trenschel, R., Thijsen, S. F. T., van Loon, A. M., Frassoni, F., Bacigalupo, A., Schaefer, U. W., et al. (2001) · Blood · doi:10.1182/blood.v98.4.972 · Cited by 373
Levine, G. N., Steinke, E. E., Bakaeen, F. G., Bozkurt, B., Cheitlin, M. D., Conti, J. B., Foster, E., Jaarsma, T., Kloner, R. A., Lange, R. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182447787 · Cited by 328
The underutilization of cardiacmedications of proven benefit, 1990 to 2002
Stafford, R. S., & Radley, D. C. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02670-0 · Cited by 286
Sexual sequelae of general medical disorders
Basson, R., & Weijmar Schultz, W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60197-4 · Cited by 283
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Depression and Cardiovascular Disease: Healing the Broken-Hearted
Whooley, M. A. (2006) · JAMA · doi:10.1001/jama.295.24.2874 · Cited by 251
Depression and Cardiovascular Disorders
Whooley, M. A., & Wong, J. M. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185526 · Cited by 241
“Some medications, such as interferon alpha, corticosteroids, and benzodiazepines, are associated with depression (Loftis & Hauser 2004, Patten & Love 1993), but the anecdotal belief that betablocker therapy causes depressive symptoms is not supported by data from clinical trials (Ko et al. 2002).”
BackgroundLampert, R., Chung, E. H., Ackerman, M. J., Arroyo, A. R., Darden, D., Deo, R., Dolan, J., Etheridge, S. P., Gray, B. R., Harmon, K. G., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.05.018 · Cited by 167
Horn, S. R., Long, M. M., Nelson, B. W., Allen, N. B., Fisher, P. A., & Byrne, M. L. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.016 · Cited by 129
Psychopharmacology and Cardiovascular Disease
Piña, I. L., Di Palo, K. E., & Ventura, H. O. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.458 · Cited by 126
Yoris, A., Abrevaya, S., Esteves, S., Salamone, P., Lori, N., Martorell, M., Legaz, A., Alifano, F., Petroni, A., Sánchez, R., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.23933 · Cited by 66
Ried, L. D., Tueth, M. J., Handberg, E., Kupfer, S., & Pepine, C. J. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000160468.69451.7f · Cited by 63
Fatigue and physical activity in older women after myocardial infarction
Crane, P. B. (2005) · Heart & Lung · doi:10.1016/j.hrtlng.2004.08.007 · Cited by 58
Metadata
- Authors
- Ko, D. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-17
- Volume
- 288
- Issue
- 3
- Pages
- 351
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2016102355
- Cited by
- 556
- References
- 34
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.